Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: A pilot study

Clinical Infectious Diseases

Volumn 35, Issue 8, 2002, Pages 960-965

  Bozkaya, Hakan ^a   Yurdaydin, Cihan ^a   Bozdayi, Abdullah Mithat ^a   Erkan, Ozlem ^a   Karayalcin, Selim ^a   Uzunalimoglu, Ozden ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GANCICLOVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; PILOT STUDY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; PILOT PROJECTS;

EID: 0037108601     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342907     Document Type: Article

References (24)

1. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-402.
2. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997; 27:431-6.
3. Lok ASF. Hepatitis B infection: pathogenesis and treatment. J Hepatol 2000;32(Suppl 1):89-97.
4. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
5. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-5.
6. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12(Suppl 1):67-71.
7. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-5.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
9. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment. Gastroenterology 2002;122:264-73.
10. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-5.
11. Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001;121:1027-8.
12. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999;68:1912-4.
13. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32: 129-34.
14. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
15. Yoshida EM, Wolber RA, Mahmood WA, Anderson FA, Scudamore CH, Erb SR. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir. Transplantation 1994;58:956-8.
16. Jamal H, Regenstein F, Farr G, Perrillo RP. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Am J Gastroenterol 1996;91:1027-30.
17. Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996;23: 1-7.
18. Roche B, Samuel D, Gigou M, et al. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J Hepatol 1999; 31:584-92.
19. Hadziyannis SJ, Manesis EK, Papakonstantinou A. Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. J Hepatol 1999;31:210-4.
20. Oon CJ, Chen WN, Lim N, et al. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the "a" epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 1999;41:113-8.
21. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990;64:613-20.
22. Hadziyannis S, Alexopoulou A, Papakonstantinou A, Petraki K, Manesis E. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study. J Viral Hepat 2000;7:235-40.
23. Bozdayi AM, Bozkaya H, Turkyilmaz, et al. Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. J Clin Virol 2001;21:91-101.
24. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-6.